<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FR940627-0-00258</title>
	</head>
	<body>
		<main>
			<p><!-- PJG STAG 4700 -->  <!-- PJG ITAG l=26 g=1 f=1 --> (10) Zeman, W., Innes, J.R.M. Craigie's Neuroanatomy of the  <!-- PJG 0012 frnewline --> Rat. (New York: Academic, 1963).  <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=80 g=1 f=1 --> &sect;79.67  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=89 g=1 f=1 --> Glial fibrillary acidic protein assay.  <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> (a)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Purpose.  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> Chemical-induced injury of the nervous  <!-- PJG 0012 frnewline --> system,  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> i.e.,  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> the brain, is associated with astrocytic  <!-- PJG 0012 frnewline --> hypertrophy at the site of damage (see O'Callaghan, 1988 in  <!-- PJG 0012 frnewline --> paragraph (e)(3) in this section). Assays of glial fibrillary  <!-- PJG 0012 frnewline --> acidic protein (GFAP), the major intermediate filament protein of  <!-- PJG 0012 frnewline --> astrocytes, can be used to document this response. To date, a  <!-- PJG 0012 frnewline --> diverse variety of chemical insults known to be injurious to the  <!-- PJG 0012 frnewline --> central nervous system have been shown to increase GFAP.  <!-- PJG 0012 frnewline --> Moreover, increases in GFAP can be seen at concentrations below  <!-- PJG 0012 frnewline --> those necessary to produce cytopathology as determined by routine  <!-- PJG 0012 frnewline --> Nissl stains (standard neuropathology). Thus it appears that  <!-- PJG 0012 frnewline --> assays of GFAP represent a sensitive approach for documenting the  <!-- PJG 0012 frnewline --> existence and location of chemical-induced injury of the central  <!-- PJG 0012 frnewline --> nervous system. Additional functional, histopathological, and  <!-- PJG 0012 frnewline --> biochemical tests are necessary to assess completely the  <!-- PJG 0012 frnewline --> neurotoxic potential of any chemical. This biochemical test is  <!-- PJG 0012 frnewline --> intended to be used in conjunction with neurohistopathological  <!-- PJG 0012 frnewline --> studies.  <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline --> (b)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Principle of the test method.  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> (1) This guideline describes the conduct of a radioimmunoassay for measurement of the amount of GFAP in the  <!-- PJG 0012 frnewline --> brain of vehicle emission-exposed and unexposed control animals. It is based on modifications (O'Callaghan &amp; Miller 1985 in paragraph (e)(5), O'Callaghan 1987 in paragraph (e)(1) of this section) of the dot-immunobinding procedure described by Jahn  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> et al. <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  (1984) in paragraph (e)(2) of this section. Briefly, brain tissue samples from study animals are assayed for total protein,  <!-- PJG 0012 frnewline --> diluted in dot-immunobinding buffer, and applied to nitrocellulose sheets. The spotted sheets are then fixed, blocked, washed and incubated in anti-GFAP antibody and [I <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=5 f=1 --> 125 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> ] Protein A. Bound protein A is then quantified by gamma  <!-- PJG 0012 frnewline --> spectrometry. In lieu of purified protein standards, standard curves are constructed from dilution of a single control sample. By comparing the immunoreactivity of individual samples (both control and exposed groups) with that of the sample used to generate the standard curve, the relative immunoreactivity of each sample is obtained. The immunoreactivity of the control groups is normalized to 100 percent and all data are expressed as  <!-- PJG 0012 frnewline --> a percentage of control. A variation on this radioimmunoassay procedure has been proposed (O'Callaghan 1991 in paragraph (e)(4) of this section) which uses a ``sandwich'' of GFAP, anti-GFAP, and a chromophore in a microtiter plate format enzyme-link immunosorbent assay (ELISA). The use of this variation shall be justified.  <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline --> (2) This assay may be done separately or in combination  <!-- PJG 0012 frnewline --> with the subchronic toxicity study, pursuant to the provisions of  <!-- PJG 0012 frnewline --> &sect;79.62.  <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline --> (c)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Test procedure_ <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> (1)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Animal selection_ <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> (i)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Species and strain.  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> Test shall be performed on the species being used in concurrent testing for neurotoxic or other health effect endpoints. This will generally be a species of laboratory rat. The use of other rodent or non-rodent species  <!-- PJG 0012 frnewline --> shall be justified.  <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline --> (ii)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Age.  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> Based on other concurrent testing, young adult  <!-- PJG 0012 frnewline --> rats shall be used. Study rodents shall not be older than ten  <!-- PJG 0012 frnewline --> weeks at the start of exposures.  <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline --> (iii)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Number of animals.  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> A minimum of ten animals per  <!-- PJG 0012 frnewline --> group shall be used. The tissues from each animal shall be  <!-- PJG 0012 frnewline --> examined separately.  <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline --> (iv)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Sex.  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> Both sexes shall be used unless it is  <!-- PJG 0012 frnewline --> demonstrated that one sex is refractory to the effects.  <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline --> (2)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Materials.  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> The materials necessary to perform this  <!-- PJG 0012 frnewline --> study are [I <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=5 f=1 --> 125 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> ] Protein A (2&hyph;10 &mu;Ci/&mu;g), Anti-sera to GFAP,  <!-- PJG 0012 frnewline --> nitrocellulose paper (0.1 or 0.2 &mu;m pore size), sample  <!-- PJG 0012 frnewline --> application template (optional; e.g., ``Minifold II'', Schleicher &amp;  <!-- PJG 0012 frnewline --> Schuell, Keene, NH), plastic sheet incubation trays.  <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline --> (3)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Study conduct.  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> (i) All data developed within this study shall be in accordance with good laboratory practice provisions under &sect; <!-- PJG 0012 frnewline --> 79.60.  <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline --> (ii)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Tissue Preparation.  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> Animals are euthanized 24 hours  <!-- PJG 0012 frnewline --> after the last exposure and the brain is excised from the skull.  <!-- PJG 0012 frnewline --> On a cold dissecting platform, the following six regions are  <!-- PJG 0012 frnewline --> dissected freehand: cerebellum; cerebral cortex; hippocampus;  <!-- PJG 0012 frnewline --> striatum; thalamus/hypothalamus; and the rest of the brain. Each  <!-- PJG 0012 frnewline --> region is then weighed and homogenized in 10 volumes of hot (70&hyph; <!-- PJG 0012 frnewline --> 90  <!-- PJG 0040 degreeslatlong --> &cir;C) 1 percent (w/v) sodium dodecyl sulfate (SDS).  <!-- PJG 0012 frnewline --> Homogenization is best achieved through sonic disruption. A  <!-- PJG 0012 frnewline --> motor driven pestle inserted into a tissue grinding vessel is a  <!-- PJG 0012 frnewline --> suitable alternative. The homogenized samples can then be stored  <!-- PJG 0012 frnewline --> frozen at ^70  <!-- PJG 0040 degreeslatlong --> &cir;C for at least 4 years without loss of GFAP  <!-- PJG 0012 frnewline --> content.  <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline --> (iii)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Total Protein Assay.  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> Aliquots of the tissue samples  <!-- PJG 0012 frnewline --> are assayed for total protein using the method of Smith  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> et al.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> (1985) in paragraph (e)(7) of this section. This assay may be  <!-- PJG 0012 frnewline --> purchased in kit form (e.g., Pierce Chemical Company, Rockford,  <!-- PJG 0012 frnewline --> IL).  <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline --> (iv)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Sample Preparation.  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> Dilute tissue samples in sample  <!-- PJG 0012 frnewline --> buffer (120 mM KCl, 20 mM NaCl, 2 mM MgCl <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=5 f=2 --> 2 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> ), 5 mM Hepes, pH 7.4,  <!-- PJG 0012 frnewline --> 0.7 percent Triton X&hyph;100) to a final concentration of 0.25 mg  <!-- PJG 0012 frnewline --> total protein per ml (5 &mu;g/20 &mu;l).  <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG /STAG --></p>
		</main>
</body></html>
            